Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
CytoMed Therapeutics Analyst Ratings
Benchmark Initiates Coverage On CytoMed Therapeutics With Speculative Buy Rating, Announces Price Target of $5
CytoMed Therapeutics Analyst Ratings
No Data